News
Infertility and long-term health problems – study
A new study is investigating the links between infertility and long-term health issues in Hispanic women of Mexican heritage.
Research suggests that female infertility is often associated with greater risks of cancer, cardiovascular disease and premature mortality. Hispanic women are up to 70 per cent more likely to experience infertility than white women, yet little is known about their long-term health.
They also will investigate the risk of heart disease and premature mortality for women with a history of infertility.
Researchers hope to determine the risk of breast cancer and gynecological cancers, including endometrial and ovarian cancer, for women with a history of infertility compared with those who have given birth.
Associate professor Leslie Farland said: “Hispanics are the largest minority group in the United States, and 60 per cent of Hispanics have Mexican heritage. We need to know more about infertility and related health risks in this group.
“We hope this project is the first step toward personalised screening recommendations that improve women’s health and lengthen women’s lives.”
The research project is led by University of Arizona Health Sciences and the Instituto Nacional de Salud Pública in Mexico; and is backed by a US$2.2 million National Institutes of Health grant.
The ultimate goal of the study is to inform personalised care strategies for millions in this population and improve health outcomes through early screenings and interventions.
Farland said existing research on infertility and long-term health outcomes among Hispanic women is sparse. Among the studies that have been conducted, there are key limitations, such as short follow-ups, small sample sizes and a lack of detailed information on infertility histories, diagnoses and treatments.
She has been collaborating with the Instituto Nacional de Salud Pública since 2016, including using data from the Mexican Teachers’ Cohort study. More than 115,000 women enrolled in the Mexican Teachers’ Cohort study in 2006 and are still providing data 18 years later.
“Research on this topic requires large samples with detailed, longitudinal data,” she said. “It can only be accomplished by bringing together international experts and data sources.”
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






